171 related articles for article (PubMed ID: 32637960)
1. A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic.
Alimova M; Sidhom EH; Satyam A; Dvela-Levitt M; Melanson M; Chamberlain BT; Alper SL; Santos J; Gutierrez J; Subramanian A; Grinkevich E; Bricio ER; Kim C; Clark A; Watts A; Thompson R; Marshall J; Pablo JL; Coraor J; Roignot J; Vernon KA; Keller K; Campbell A; Emani M; Racette M; Bazua-Valenti S; Padovano V; Weins A; McAdoo SP; Tam FWK; Ronco L; Wagner F; Tsokos GC; Shaw JL; Greka A
bioRxiv; 2020 Jun; ():. PubMed ID: 32637960
[TBL] [Abstract][Full Text] [Related]
2. A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.
Kost-Alimova M; Sidhom EH; Satyam A; Chamberlain BT; Dvela-Levitt M; Melanson M; Alper SL; Santos J; Gutierrez J; Subramanian A; Byrne PJ; Grinkevich E; Reyes-Bricio E; Kim C; Clark AR; Watts AJB; Thompson R; Marshall J; Pablo JL; Coraor J; Roignot J; Vernon KA; Keller K; Campbell A; Emani M; Racette M; Bazua-Valenti S; Padovano V; Weins A; McAdoo SP; Tam FWK; Ronco L; Wagner F; Tsokos GC; Shaw JL; Greka A
Cell Rep Med; 2020 Nov; 1(8):100137. PubMed ID: 33294858
[TBL] [Abstract][Full Text] [Related]
3. Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.
Tabassum N; Zhang H; Stebbing J
Cell Rep Med; 2020 Nov; 1(8):100145. PubMed ID: 33225317
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib.
Cooper N; Ghanima W; Hill QA; Nicolson PL; Markovtsov V; Kessler C
Platelets; 2023 Dec; 34(1):2131751. PubMed ID: 36331249
[TBL] [Abstract][Full Text] [Related]
5. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Pamuk ON; Can G; Ayvaz S; Karaca T; Pamuk GE; Demirtas S; Tsokos GC
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S15-22. PubMed ID: 26148346
[TBL] [Abstract][Full Text] [Related]
6. A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin C; DiCioccio RA; Haykal T; McManigle WC; Li Z; Anand SM; Poe JC; Bracken SJ; Jia W; Alyea EP; Cardones AR; Choi T; Gasparetto C; Grunwald MR; Hennig T; Kang Y; Long GD; Lopez R; Martin M; Minor KK; Quinones VLP; Sung AD; Wiggins K; Chao NJ; Horwitz ME; Rizzieri DA; Sarantopoulos S
Transplant Cell Ther; 2023 Mar; 29(3):179.e1-179.e10. PubMed ID: 36577483
[TBL] [Abstract][Full Text] [Related]
7. Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion.
Lucchesi A; Fattizzo B; De Stefano V; Ruggeri M; Siragusa S; Vianelli N; Zaja F; Rodeghiero F
Ther Adv Hematol; 2023; 14():20406207221147777. PubMed ID: 37426835
[TBL] [Abstract][Full Text] [Related]
8. Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC; Gebru T; Muslimani A
Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies.
Baluom M; Grossbard EB; Mant T; Lau DT
Br J Clin Pharmacol; 2013 Jul; 76(1):78-88. PubMed ID: 23190017
[TBL] [Abstract][Full Text] [Related]
10. Mucin 1 Inhibits Ferroptosis and Sensitizes Vitamin E to Alleviate Sepsis-Induced Acute Lung Injury through GSK3
Wang YM; Gong FC; Qi X; Zheng YJ; Zheng XT; Chen Y; Yang ZT; Qing-Ye ; Mao EQ; Chen EZ
Oxid Med Cell Longev; 2022; 2022():2405943. PubMed ID: 35910848
[TBL] [Abstract][Full Text] [Related]
11. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
[TBL] [Abstract][Full Text] [Related]
12. Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface.
Chatterjee M; Huang LZX; Mykytyn AZ; Wang C; Lamers MM; Westendorp B; Wubbolts RW; van Putten JPM; Bosch BJ; Haagmans BL; Strijbis K
PLoS Pathog; 2023 Aug; 19(8):e1011571. PubMed ID: 37561789
[TBL] [Abstract][Full Text] [Related]
13. Mucin1 relieves acute lung injury by inhibiting inflammation and oxidative stress.
Ye C; Xu B; Yang J; Liu Y; Zeng Z; Xia L; Li Q; Zou G
Eur J Histochem; 2021 Dec; 65(4):. PubMed ID: 34852453
[TBL] [Abstract][Full Text] [Related]
14. The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.
Can G; Ayvaz S; Can H; Demirtas S; Aksit H; Yilmaz B; Korkmaz U; Kurt M; Karaca T
J Crohns Colitis; 2015 Oct; 9(10):907-17. PubMed ID: 26116555
[TBL] [Abstract][Full Text] [Related]
15. A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.
Sahebnasagh A; Mojtahedzadeh M; Najmeddin F; Najafi A; Safdari M; Rezai Ghaleno H; Habtemariam S; Berindan-Neagoe I; Nabavi SM
Arch Med Res; 2020 Oct; 51(7):631-635. PubMed ID: 32863034
[TBL] [Abstract][Full Text] [Related]
16. Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Paik J
Drugs; 2021 Jun; 81(8):935-943. PubMed ID: 33970459
[TBL] [Abstract][Full Text] [Related]
17. Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN.
McAdoo SP; Reynolds J; Bhangal G; Smith J; McDaid JP; Tanna A; Jackson WD; Masuda ES; Cook HT; Pusey CD; Tam FW
J Am Soc Nephrol; 2014 Oct; 25(10):2291-302. PubMed ID: 24700868
[TBL] [Abstract][Full Text] [Related]
18. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial.
Strich JR; Tian X; Samour M; King CS; Shlobin O; Reger R; Cohen J; Ahmad K; Brown AW; Khangoora V; Aryal S; Migdady Y; Kyte JJ; Joo J; Hays R; Collins AC; Battle E; Valdez J; Rivero J; Kim IH; Erb-Alvarez J; Shalhoub R; Chakraborty M; Wong S; Colton B; Ramos-Benitez MJ; Warner S; Chertow DS; Olivier KN; Aue G; Davey RT; Suffredini AF; Childs RW; Nathan SD
Clin Infect Dis; 2022 Aug; 75(1):e491-e498. PubMed ID: 34467402
[TBL] [Abstract][Full Text] [Related]
19. The Efficacy and Safety of Fostamatinib in Elderly Patients with Immune Thrombocytopenia: A Single-Center, Real-World Case Series.
Liu J; Hsia CC
Adv Hematol; 2022; 2022():8119270. PubMed ID: 36393999
[TBL] [Abstract][Full Text] [Related]
20. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
